Effectiveness and Safety of Hypofractionated Radiotherapy in Patients With Ductal Carcinoma In Situ (DCIS)
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/9456822 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Breast Journal, online erschienen am 08.06.2026. Verfasst von Reza Samiee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Radiation Dose Hypofractionation. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To synthesize the available evidence on the oncologic outcomes, toxicity, and cosmesis of hypofractionated whole‐breast irradiation (HF‐WBI) in patients with ductal carcinoma in situ (DCIS) following breast‐conserving surgery (BCS).
Methods
A systematic review and meta‐analysis was conducted according to PRISMA guidelines. PubMed, Embase, and Web of Science were searched from inception until July 12, 2025. We included studies of DCIS patients treated with BCS followed by HF‐WBI (fraction size > 2.0 Gy). Both comparative studies (against conventional fractionation [CF]) and single‐arm studies reporting outcomes for HF‐WBI alone were included. Pooled incidence rates for outcomes from single‐arm studies and pooled hazard ratios (HRs) or odds ratios (ORs) from the limited comparative studies were calculated using random‐effects models.
Results
Nineteen studies were included. Local control and overall survival were excellent and equivalent between HF‐WBI and CF‐WBI. The pooled HR for local recurrence comparing ultrahypofractionation to CF was 0.89 (95% CI 0.64–1.24). HF‐WBI significantly reduced the odds of acute dermatitis (OR 0.22, 95% CI 0.13–0.35). Late toxicities were infrequent (e.g., telangiectasia: 2%, 95% CI 0%–5%). Good/excellent cosmesis was reported in 90% (95% CI 84%–94%) of patients.
Conclusion
HF‐WBI is a safe and effective treatment for DCIS, achieving oncologic outcomes equivalent to CF while offering improved tolerability, reduced acute skin toxicity, and excellent cosmetic results. These benefits, combined with increased convenience and potential cost savings, support the integration of HF‐WBI into standard practice for DCIS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar Di Valpolicella, Verona, Italy, sacrocuore.it.
- Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
ORCID-Profile: Reza Samiee, Mohammadamin Kharaghani, Amirhossein Shahsavand, Shayan Forghani, Mehrdad Mozafar, Negin Safari Dehnavi, Zahra Ghanbari, Luca Nicosia, Fatemeh Jafari
Zitieren
APA
Samiee, R., Kharaghani, M., Shahsavand, A., Forghani, S., Mozafar, M., Dehnavi, N. S., Ghanbari, Z., Nicosia, L., & Jafari, F. (2026). Effectiveness and Safety of Hypofractionated Radiotherapy in Patients With Ductal Carcinoma In Situ (DCIS). The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/9456822
Vancouver
Samiee R, Kharaghani M, Shahsavand A, Forghani S, Mozafar M, Dehnavi NS, et al. Effectiveness and Safety of Hypofractionated Radiotherapy in Patients With Ductal Carcinoma In Situ (DCIS). The Breast Journal. 2026;2026(1). doi:10.1155/tbj/9456822
BibTeX
@article{Samiee2026,
author = {Samiee, Reza and Kharaghani, Mohammadamin and Shahsavand, Amirhossein and Forghani, Shayan and Mozafar, Mehrdad and Dehnavi, Negin Safari and Ghanbari, Zahra and Nicosia, Luca and Jafari, Fatemeh},
title = {Effectiveness and Safety of Hypofractionated Radiotherapy in Patients With Ductal Carcinoma In Situ (DCIS)},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/9456822}
}
EUVIMED